JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Abstract

Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing. Several other JAK2 inhibitors have entered clinical testing, but none have been approved and many have been discontinued. Importantly, the activity of these agents is not restricted to patients with JAK2 V617F or exon 12 mutations. Although JAK2 inhibitors provide substantial clinical benefit, their disease-modifying activity is limited, and rational combinations with other targeted agents are needed, particularly in MF, in which survival is short. Many such combinations are being explored, as are other novel agents, some of which could successfully be combined with JAK2 inhibitors in the future. In addition, new JAK2 inhibitors with the potential for less myelosuppression continue to be investigated. Given the proven safety and efficacy of ruxolitinib, it is likely that ruxolitinib-based combinations will be a major way forward in drug development for MF. If approved, less myelosuppressive JAK2 inhibitors such as pacritinib or NS-018 could prove to be very useful additions to the therapeutic armamentarium in MF. In PV, inhibitors of histone deacetylases and human double minute 2 have activity, but their role, if any, in the future treatment algorithm is uncertain, given the availability of ruxolitinib and renewed interest in interferons. Ruxolitinib is in late-phase clinical trials in essential thrombocythemia, in which it could fill an important void for patients with troublesome symptoms.

• Authors: Prithviraj Bose, Srdan Verstovsek
• Journal: Blood (Blood) Vol. 130 Issue 2 Pg. 115-125 (07 13 2017) ISSN: 1528-0020 [Electronic] United States
• PMID: 28500170 (Publication Type: Journal Article, Review)
• Copyright: © 2017 by The American Society of Hematology.

Chemical References

• 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
• Antineoplastic Agents
• Bridged-Ring Compounds
• Nitriles
• Protein Kinase Inhibitors
• Pyrazoles
• Pyrimidines
• ruxolitinib
• JAK1 protein, human
• JAK2 protein, human
• Janus Kinase 1
• Janus Kinase 2

Topics

• Antineoplastic Agents (therapeutic use)
• Bridged-Ring Compounds (therapeutic use)
• Gene Expression
• Humans
• Janus Kinase 1 (antagonists & inhibitors, genetics, metabolism)
• Janus Kinase 2 (antagonists & inhibitors, genetics, metabolism)
• Mutation
• Nitriles
• Patient Safety
• Polycythemia Vera (drug therapy, enzymology, genetics, pathology)
• Primary Myelofibrosis (drug therapy, enzymology, genetics, pathology)
• Protein Kinase Inhibitors (therapeutic use)
• Pyrazoles (therapeutic use)
• Pyrimidines (therapeutic use)
• Randomized Controlled Trials as Topic
• Thrombocythemia, Essential (drug therapy, enzymology, genetics, pathology)
• Treatment Outcome